Evidence map›Paper›PMID 28129483›Full record

ArticleArthritis care & research2017

Association of Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Autoantibodies With DRB1*07:01 and Severe Myositis in Juvenile Myositis Patients.

Takayuki Kishi, Lisa G Rider, Katherine Pak, Lilliana Barillas-Arias, Michael Henrickson, Paul L McCarthy, Bracha Shaham, Pamela F Weiss, Iren Horkayne-Szakaly, Ira N Targoff and 3 more

Abstract read
In one paragraph

Article in Arthritis care & research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 96 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 9 institutions in 1 country.

Takayuki KishiNational Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, Maryland.
Lisa G RiderNational Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, Maryland.
Katherine PakLaboratory of Muscle Stem Cells and Gene Expression, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland.
Lilliana Barillas-AriasAlbany Medical Center, Albany, New York.
Michael HenricksonCincinnati Children's Medical Center, Cincinnati, OH.
Paul L McCarthyYale University School of Medicine, New Haven, Connecticut.
Bracha ShahamChildren's Hospital of Los Angeles, Los Angeles, California.
Pamela F WeissChildren's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Iren Horkayne-SzakalyJoint Pathology Center, Defense Health Agency, Silver Spring, Maryland.
Ira N TargoffVeterans Affairs Medical Center, University of Oklahoma Health Sciences Center, and Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma.
Frederick W MillerNational Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, Maryland.
Andrew L MammenLaboratory of Muscle Stem Cells and Gene Expression, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland.
Childhood Myositis Heterogeneity Study Group
National Institute of Arthritis and Musculoskeletal and Skin Diseases · USNational Institutes of Health · USAlbany Medical Center Hospital · USChildren's Hospital of Los Angeles · USChildren's Hospital of Philadelphia · USCincinnati Children's Hospital Medical Center · USDefense Health Agency · USNational Institute of Environmental Health Sciences · USYale University · US

Funding

Environmental/genetic Risk Factors and Pathogenesis of Autoimmune DiseaseZIAES101074 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI RIDER, LISA · 2009 to 2025
$34.6M
Muscle Disease UnitZIAAR041203 · NIAMS · NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES · PI MAMMEN, ANDREW · 2015 to 2025
$19.7M
Pathogenesis And Genetic/environmental Risk Factors ForZ01ES101074 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI MILLER, FREDERICK · 2002 to 2008
$2.7M
Intramural NIH HHS Z01 ES101074Intramural NIH HHS Z99 ES999999Intramural NIH HHS ZIA AR041203
6 · The paper itself

Abstract

objectiveAutoantibodies recognizing 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) are associated with statin exposure, the HLA allele DRB1*11:01, and necrotizing muscle biopsies in adult myositis patients. The aim of this study was to characterize the features of juvenile anti-HMGCR-positive myositis patients.

methodsThe sera of 440 juvenile myositis patients were screened for anti-HMGCR autoantibodies. Demographic and clinical features, responses to therapy, and HLA alleles were assessed. The features of anti-HMGCR-positive patients were compared to those of previously described adult patients with this autoantibody and to children with other myositis-specific autoantibodies (MSAs).

resultsFive of 440 patients (1.1%) were anti-HMGCR-positive; none had taken statin medications. Three patients had rashes characteristic of juvenile dermatomyositis and 2 patients had immune-mediated necrotizing myopathies. The median highest creatine kinase (CK) level of anti-HMGCR-positive subjects was 17,000 IU/liter. All patients had severe proximal muscle weakness, distal weakness, muscle atrophy, joint contractures, and arthralgias, which were all more prevalent in HMGCR-positive subjects compared to MSA-negative patients or those with other MSAs. Anti-HMGCR-positive patients had only partial responses to multiple immunosuppressive medications, and their disease often took a chronic course. The DRB1*07:01 allele was present in all 5 patients, compared to 26.25% of healthy controls (corrected P = 0.01); none of the 5 juvenile patients had DRB1*11:01.

conclusionCompared to children with other MSAs, muscle disease appears to be more severe in those with anti-HMGCR autoantibodies. Like adults, children with anti-HMGCR autoantibodies have severe weakness and high CK levels. In contrast to adults, in anti-HMGCR-positive children, there is a strong association with HLA-DRB1*07:01.

Indexed as

Severity of Illness IndexAcyl Coenzyme AAdolescentAutoantibodiesBiomarkersChildChild, PreschoolFemaleHumansMaleMyositisNerve Tissue ProteinsRNA-Binding Proteins3-hydroxy-3-methylglutaryl-coenzyme AAcyl Coenzyme AAutoantibodiesBiomarkersNerve Tissue ProteinsRBM45 protein, humanRNA-Binding Proteins

Identifiers

PMID28129483
PMCPMC5487292
OpenAlexW2741842157

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.